EMA: Granting of a marketing authorisation for the medicinal product Siltuximab [Sylvant] for the treatment of multicentric Castleman’s Disease (MCD) recommended.
On 20 March 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Sylvant, 100 mg and 400 mg, Powder for concentrate for solution for …